Literature DB >> 16261283

Tryptophan degradation increases with stage in patients with rheumatoid arthritis.

Katharina Schroecksnadel1, Christiana Winkler, Christian Duftner, Barbara Wirleitner, Michael Schirmer, Dietmar Fuchs.   

Abstract

Immune system activation is known to be involved in the progression of rheumatoid arthritis (RA). The proinflammatory cytokine interferon-gamma in various cells, including monocytes, induces the enzyme indoleamine (2,3)-dioxygenase (IDO), which converts tryptophan to kynurenine. In sera of 22 patients (17 women and 5 men) with RA stages 1 to 4 according to Steinbrocker, the concentrations of tryptophan and kynurenine were measured by high-pressure liquid chromatography. To estimate IDO activity, the kynurenine to tryptophan ratio (kyn/trp) was calculated. In parallel, concentrations of the macrophage activation marker neopterin were determined by enzyme-linked immunosorbent assay. Tryptophan concentrations were lower in patients with RA, and the decrease in serum tryptophan correlated with increase in stage (p<0.05). Kyn/trp correlated well with neopterin concentrations, which were elevated in most patients. Whereas higher C-reactive protein concentrations and erythrocyte sedimentation rates were observed in patients with greater disease activity, tryptophan and neopterin concentrations did not differ between patients with different subjective disease activity graded by the physician. Deficiency of the essential amino acid tryptophan in patients with RA most likely results from immune activation involved in the pathogenesis of the disease. It could also be relevant for the mood of patients, as tryptophan is the precursor of serotonin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16261283     DOI: 10.1007/s10067-005-0056-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  Soluble adhesion molecules in rheumatoid arthritis.

Authors:  E L Nassonov; M Y Samsonov; N V Chichasova; E L Nikiphorova; G P Tilz; U Demel; B Widner; D Fuchs
Journal:  Rheumatology (Oxford)       Date:  2000-07       Impact factor: 7.580

2.  Monocyte-derived dendritic cells release neopterin.

Authors:  Barbara Wirleitner; Daniela Reider; Susanne Ebner; Günther Böck; Bernhard Widner; Matthias Jaeger; Harald Schennach; Nikolaus Romani; Dietmar Fuchs
Journal:  J Leukoc Biol       Date:  2002-12       Impact factor: 4.962

3.  Simultaneous measurement of serum tryptophan and kynurenine by HPLC.

Authors:  B Widner; E R Werner; H Schennach; H Wachter; D Fuchs
Journal:  Clin Chem       Date:  1997-12       Impact factor: 8.327

4.  Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma.

Authors:  E R Werner; G Werner-Felmayer; D Fuchs; A Hausen; G Reibnegger; H Wachter
Journal:  Biochem J       Date:  1989-09-15       Impact factor: 3.857

Review 5.  Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?

Authors:  A L Mellor; D H Munn
Journal:  Immunol Today       Date:  1999-10

6.  Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity.

Authors:  L A Rubin; K M Snow; C C Kurman; D L Nelson; E C Keystone
Journal:  J Rheumatol       Date:  1990-05       Impact factor: 4.666

7.  Correlation of interleukin-2 receptor and neopterin secretion in rheumatoid arthritis.

Authors:  W Kullich
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

8.  The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo.

Authors:  F Burke; R G Knowles; N East; F R Balkwill
Journal:  Int J Cancer       Date:  1995-01-03       Impact factor: 7.396

9.  Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis.

Authors:  G Steiner; A Studnicka-Benke; G Witzmann; E Höfler; J Smolen
Journal:  J Rheumatol       Date:  1995-03       Impact factor: 4.666

10.  Inhibition of T cell proliferation by macrophage tryptophan catabolism.

Authors:  D H Munn; E Shafizadeh; J T Attwood; I Bondarev; A Pashine; A L Mellor
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

View more
  41 in total

Review 1.  Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.

Authors:  G C Prendergast; M Y Chang; L Mandik-Nayak; R Metz; A J Muller
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activity.

Authors:  Nitin K Gupta; Ameet I Thaker; Navya Kanuri; Terrence E Riehl; Christopher W Rowley; William F Stenson; Matthew A Ciorba
Journal:  Inflamm Bowel Dis       Date:  2011-08-05       Impact factor: 5.325

Review 3.  Biomarkers in inflammatory bowel disease: current practices and recent advances.

Authors:  Heba N Iskandar; Matthew A Ciorba
Journal:  Transl Res       Date:  2012-02-01       Impact factor: 7.012

Review 4.  Amino acid catabolism: a pivotal regulator of innate and adaptive immunity.

Authors:  Tracy L McGaha; Lei Huang; Henrique Lemos; Richard Metz; Mario Mautino; George C Prendergast; Andrew L Mellor
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

5.  1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis.

Authors:  Elizabeth Pigott; James B DuHadaway; Alexander J Muller; Susan Gilmour; George C Prendergast; Laura Mandik-Nayak
Journal:  Autoimmunity       Date:  2014-05-06       Impact factor: 2.815

6.  Myeloid differentiation primary response protein 88 blockade upregulates indoleamine 2,3-dioxygenase expression in rheumatoid synovial fibroblasts.

Authors:  Mi-Kyung Park; Hye-Jwa Oh; Yang-Mi Heo; Eun-Mi Park; Mi-La Cho; Ho-Youn Kim; Sung-Hwan Park
Journal:  Exp Mol Med       Date:  2011-08-31       Impact factor: 8.718

7.  Addition of an indoleamine 2,3,-dioxygenase inhibitor to B cell-depletion therapy blocks autoreactive B cell activation and recurrence of arthritis in K/BxN mice.

Authors:  Elizabeth Pigott; Laura Mandik-Nayak
Journal:  Arthritis Rheum       Date:  2012-07

Review 8.  Modulation of autoimmune arthritis by environmental 'hygiene' and commensal microbiota.

Authors:  David Langan; Eugene Y Kim; Kamal D Moudgil
Journal:  Cell Immunol       Date:  2018-12-10       Impact factor: 4.868

9.  Serum level of neopterin is not a marker of disease activity in treated rheumatoid arthritis patients.

Authors:  Dalia El-Lebedy; Jihan Hussein; Ingy Ashmawy; Asmaa M Mohammed
Journal:  Clin Rheumatol       Date:  2016-10-03       Impact factor: 2.980

10.  The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity.

Authors:  Grant N Scott; James DuHadaway; Elizabeth Pigott; Natalie Ridge; George C Prendergast; Alexander J Muller; Laura Mandik-Nayak
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.